MedPage Today November 11, 2024
Sentynl Therapeutics, Inc.

About Dr. Wendy Chung and the GUARDIAN Study

Hello, I’m Dr. Liza Squires, a Medical Consultant at Sentynl Therapeutics, a U.S.-based biopharmaceutical company focused on rare disease.

Today, I’m here with Dr. Wendy Chung, a clinical and molecular geneticist and Chief of the Department of Pediatrics at Boston Children’s Hospital and Harvard Medical School. Today, we’ll discuss the importance of advancing newborn screening with whole genome sequencing, and how healthcare providers can advocate for this important advancement.

Dr. Chung, thank you for your time. Could you share a bit about your background and work in newborn screening and genetics?

Dr. Chung

Thanks Liza, it’s good to be here. For the past 35 years, I’ve dedicated my career to genetics and...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Conferences / Podcast, Pharma / Biotech, Precision Medicine, Survey / Study, Trends
AI In Healthcare: A New Era Of Personalized Patient Care
23andMe reports sales decline a day after announcing plans to cut 40% of workforce
Patient-derived organoids: Transforming cancer research and personalized medicine
Cracking the code of DNA circles in cancer: Scientists uncover potential therapy
Personalized Medicine: Past, Present, and Future

Share This Article